Michael F. Clarke

Michael F. Clarke

Auto-generated profile, based on publicly available information

Michael F. Clarke

Institute for Stem Cell Biology and Regenerative Medicine, School of Medicine, Stanford University, Stanford, CA 94305, USA

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 April 2009 in Nature
Verified
Journal Article
Closed access
PDF file
MDMaximilian Diehn
Maximilian Diehn
RCRobert W. Cho
Robert W. Cho
NLNeethan A. Lobo
Neethan A. Lobo
TKTomer Kalisky
Tomer Kalisky
MDMary Jo Dorie
Mary Jo Dorie
MCMichael F. Clarke
Michael F. Clarke

24 January 2020 in Science
Verified
Journal Article
Closed access
PDF file
GGGunsagar S. Gulati
Gunsagar S. Gulati
SSShaheen S. Sikandar
Shaheen S. Sikandar
DWDaniel J. Wesche
Daniel J. Wesche
AMAnoop Manjunath
Anoop Manjunath
ABAnjan Bharadwaj
Anjan Bharadwaj
ANAaron M. Newman
Aaron M. Newman
More diversity at the top: A detailed knowledge of cell differentiation hierarchies is important for understanding diverse biological processes such as organ development, tissue regeneration, and cancer. Single-cell RNA sequencing can help elucidate these hierarchies, but it requires reliable computational methods for predicting cell lineage trajectories. Gulati et al. developed CytoTRACE, a computational framework based on the simple observation that transcriptional diversity—the number of genes expressed in a cell—decreases during differentiation. CytoTRACE outperformed other methods in several test cases and was successfully applied to study cellular hierarchies in healthy and tumor tissue. Science , this issue p. 405

12 June 2007 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
PDPiero Dalerba
Piero Dalerba
SDScott J. Dylla
Scott J. Dylla
IPIn-Kyung Park
In-Kyung Park
RLRui Liu
Rui Liu
XWXinhao Wang
Xinhao Wang
MCMichael F. Clarke
Michael F. Clarke
Recent observations indicate that, in several types of human cancer, only a phenotypic subset of cancer cells within each tumor is capable of initiating tumor growth. This functional subset of cancer cells is operationally defined as the “cancer stem cell” (CSC) subset. Here we developed a CSC model for the study of human colorectal cancer (CRC). Solid CRC tissues, either primary tissues collected from surgical specimens or xenografts established in nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice, were disaggregated into single-cell suspensions and analyzed by flow cytometry. Surface markers that displayed intratumor heterogeneous expression among epithelial cancer cells were selected for cell sorting and tumorigenicity experiments. Individual phenotypic cancer cell subsets were purified, and their tumor-initiating properties were investigated by injection in NOD/SCID mice. Our observations indicate that, in six of six human CRC tested, the ability to engraft in vivo in immunodeficient mice was restricted to a minority subpopulation of epithelial cell adhesion molecule (EpCAM) high /CD44 + epithelial cells. Tumors originated from EpCAM high /CD44 + cells maintained a differentiated phenotype and reproduced the full morphologic and phenotypic heterogeneity of their parental lesions. Analysis of the surface molecule repertoire of EpCAM high /CD44 + cells led to the identification of CD166 as an additional differentially expressed marker, useful for CSC isolation in three of three CRC tested. These results validate the stem cell working model in human CRC and provide a highly robust surface marker profile for CRC stem cell isolation.

1 August 2009 in Cell
Verified
Journal Article
Closed access
YSYohei Shimono
Yohei Shimono
MZMaider Zabala
Maider Zabala
RCRobert W. Cho
Robert W. Cho
NLNeethan Lobo
Neethan Lobo
PDPiero Dalerba
Piero Dalerba
MCMichael F. Clarke
Michael F. Clarke

1 March 2006 in Cell
Verified
Journal Article
Closed access
MCMichael F. Clarke
Michael F. Clarke
MFMargaret Fuller
Margaret Fuller

21 January 2016 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
PDPiero Dalerba
Piero Dalerba
DSDebashis Sahoo
Debashis Sahoo
SPSoonmyung Paik
Soonmyung Paik
XGXiangqian Guo
Xiangqian Guo
GYGreg Yothers
Greg Yothers
MCMichael F. Clarke
Michael F. Clarke
The identification of high-risk stage II colon cancers is key to the selection of patients who require adjuvant treatment after surgery. Microarray-based multigene-expression signatures derived from stem cells and progenitor cells hold promise, but they are difficult to use in clinical practice. We used a new bioinformatics approach to search for biomarkers of colon epithelial differentiation across gene-expression arrays and then ranked candidate genes according to the availability of clinical-grade diagnostic assays. With the use of subgroup analysis involving independent and retrospective cohorts of patients with stage II or stage III colon cancer, the top candidate gene was tested for its association with disease-free survival and a benefit from adjuvant chemotherapy. The transcription factor CDX2 ranked first in our screening test. A group of 87 of 2115 tumor samples (4.1%) lacked CDX2 expression. In the discovery data set, which included 466 patients, the rate of 5-year disease-free survival was lower among the 32 patients (6.9%) with CDX2-negative colon cancers than among the 434 (93.1%) with CDX2-positive colon cancers (hazard ratio for disease recurrence, 3.44; 95% confidence interval [CI], 1.60 to 7.38; P=0.002). In the validation data set, which included 314 patients, the rate of 5-year disease-free survival was lower among the 38 patients (12.1%) with CDX2 protein–negative colon cancers than among the 276 (87.9%) with CDX2 protein–positive colon cancers (hazard ratio, 2.42; 95% CI, 1.36 to 4.29; P=0.003). In both these groups, these findings were independent of the patient’s age, sex, and tumor stage and grade. Among patients with stage II cancer, the difference in 5-year disease-free survival was significant both in the discovery data set (49% among 15 patients with CDX2-negative tumors vs. 87% among 191 patients with CDX2-positive tumors, P=0.003) and in the validation data set (51% among 15 patients with CDX2-negative tumors vs. 80% among 106 patients with CDX2-positive tumors, P=0.004). In a pooled database of all patient cohorts, the rate of 5-year disease-free survival was higher among 23 patients with stage II CDX2-negative tumors who were treated with adjuvant chemotherapy than among 25 who were not treated with adjuvant chemotherapy (91% vs. 56%, P=0.006). Lack of CDX2 expression identified a subgroup of patients with high-risk stage II colon cancer who appeared to benefit from adjuvant chemotherapy. (Funded by the National Comprehensive Cancer Network, the National Institutes of Health, and others.)